ABSTRACT Patients with advanced endometrial cancer (EC) have a poor prognosis and limited therapeutic options after failure of prior systemic therapy. In this multi‐cohort Phase II study (ETER200), patients with metastatic or recurrent EC who had received at least one chemotherapy regimen were enrolled. Based on MSI/MM...
Shan-Hui Liang, Xiao-Jun Chen, Ke Wang et al.· MedComm· 0 citations
This randomized clinical trial found that benmelstobart with or without anlotinib significantly improved progression-free survival (PFS) compared with placebo and adding anlotinib did not significantly improve PFS compared with benmelstobart alone and increased severe and fatal treatment-related adverse events.
Yong-Ling Ji, Qi-Wen Li, Long Chen et al.· JAMA Oncology· 0 citations
The phase III ADVANCE study prospectively assessed a chemotherapy-free strategy combining aumolertinib with definitive radiotherapy (RT) in patients with unresectable stage III non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations (ChiCTR.org: ChiCTR2000040590). Participants wer...
N. Bi, Jian-Yang Wang, Wei Jiang et al.· Signal Transduction and Targ...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.